Vaccine manufacturing facilities facilitate the vaccine commercialization timeline, which spans from phase 1 trials to the launch. The challenges include: speed to market, large at launch capacity, representative commercial facility needed and the need to defer early investment to reduce sunk cost. The opportunities often outweigh the challenges: for example, multi-use facilities and modular design.
MedImmune Strategy to meet these challenge and opportunities is simple. They aim to maintain superior efficiency on current business, with continual quality improvement that allows them to improve benchmarks maintaining good supply and ensuring efficient cost of manufacturing. Being operate smarter equals operations excellence initiatives. They also aim to improve how we build pipeline capabilities, making them faster with smarter facility design and construction.
In summary, Vaccine manufacturing for new pipeline products requires very early at-risk decisions; Increasing efficiency and reliability of current operations free-ing up capacity for new products; and multiproduct strategies combined with flexible smaller foot print processing allows maximal strategic agility in accommodating new products while balancing the sunk cost versus readiness equation.
Shou-Bai Chao, Senior Vice President, Manufacturing, MedImmune joined us at the World Vaccine Congress 2013 in Washington to give details about the best practice and new benchmarks for vaccine manufacturing facilities.
Why not download the full presentation and find out all you need to know about vaccine manufacturing facilities – best practice and new benchmarks:
Â· Designing an expandable and sustainable vaccine plant for multi-product manufacturing for global expansion
Â· Implementing effective site transformation strategies
Â· Making the transition from mono-facility into multiple – which is the best option for a vaccine manufacturer and how can the associated challenges be overcome?